BACKGROUND AND AIMS: Ontamalimab, a fully-human monoclonal antibody targeting MAdCAM-1, induced remission in patients with moderate-to-severe ulcerative colitis [UC] in the TURANDOT study. We aimed to assess long-term safety, tolerability, and efficacy of ontamalimab in TURANDOT II. METHODS: TURANDOT II was a phase 2, multicentre, open-label [OL] study in patients with moderate-to-severe UC who completed TURANDOT on placebo or ontamalimab (NCT01771809). Patients were randomised to 75 mg or 225 mg ontamalimab every 4 weeks for 72 weeks [OL1]. The dosage could be increased to 225 mg from Week 8 at the investigator's discretion. All patients then received 75 mg every 4 weeks for 72 weeks [OL2], followed by 6-month safety follow-up. The primary objective was safety, measured by adverse events [AEs], serious AEs [SAEs], and AEs leading to withdrawal. Mucosal healing [MH; centrally read endoscopy] was assessed. RESULTS: Of 330 patients, 180 completed OL1; 94 escalated to 225 mg; 127 completed OL2. Overall, 36.1% experienced drug-related AEs. The most common SAE [10.0%] was worsening/ongoing UC; 5.5% of patients had serious infections, the most common being gastroenteritis [0.9%]. One death and four cancers [all unrelated to ontamalimab] occurred. No PML [progressive multifocal leukoencephalopathy]/lymphoproliferative disorders occurred. Geometric mean high-sensitivity C-reactive protein [hsCRP] and faecal calprotectin decreased across OL1 in both dose groups. The proportion of patients assigned to placebo in TURANDOT achieving MH increased from 8.8% [6/68] at baseline to 35.3% at Week 16 [24/68; non-responder imputation]. The corresponding increase in the ontamalimab group was from 23.3% [61/262] to 26.7% [70/262]. CONCLUSIONS: Ontamalimab was well tolerated up to 144 weeks in patients with moderate-to-severe UC, with good safety and efficacy.

Clinic of Gastroenterology and Hepatology Military Medical Academy Belgrade Serbia

Cytel Inc Cambridge MA USA

Department of Gastroenterology University Hospitals Leuven Leuven Belgium

Department of Internal Medicine Medical University of Vienna Vienna Austria

Department of Medicine University of California San Diego La Jolla CA USA

Faculty of Medicine Charles University Hospital Hradec Králové Czech Republic

Gastroenterology Centre Nitra Slovakia

Gastroenterology Nature Coast Clinical Research Inverness FL USA

Inflammatory Bowel Disease Clinic Alfred Hospital Melbourne VIC Australia

Inflammatory Bowel Diseases Center Humanitas University Milan Italy

Nicolaus Copernicus University Collegium Medicum in Bydgoszcz Bydgoszcz Poland

Seoul National University College of Medicine Seoul South Korea

Shire a Takeda company Lexington MA USA

Shire a Takeda company Zug Switzerland

University of Nice Sophia Antipolis CHU of Nice Nice France

Zymo Consulting Group Newtown Square PA USA

See more in PubMed

Ungaro R, Mehandru S, Allen PB, Peyrin-Biroulet L, Colombel JF. Ulcerative colitis. Lancet 2017;389:1756–70. PubMed PMC

Paschos P, Katsoula A, Salanti G, Giouleme O, Athanasiadou E, Tsapas A. Systematic review with network meta-analysis: the impact of medical interventions for moderate-to-severe ulcerative colitis on health-related quality of life. Aliment Pharmacol Ther 2018;48:1174–85. PubMed

Peyrin-Biroulet L, Sandborn W, Sands BE, et al. . Selecting Therapeutic Targets in Inflammatory Bowel Disease [STRIDE]: determining therapeutic goals for treat-to-target. Am J Gastroenterol 2015;110:1324–38. PubMed

Dubinsky MC. Reviewing treatments and outcomes in the evolving landscape of ulcerative colitis. Postgrad Med 2017;129:538–53. PubMed

Paschos P, Katsoula A, Giouleme O, et al. . Tofacitinib for induction of remission in ulcerative colitis: systematic review and meta-analysis. Ann Gastroenterol 2018;31:572–82. PubMed PMC

Lopetuso LR, Gerardi V, Papa V, et al. . Can we predict the efficacy of anti-TNF-α agents? Int J Mol Sci 2017;18:1973. PubMed PMC

Ben-Horin S, Kopylov U, Chowers Y. Optimizing anti-TNF treatments in inflammatory bowel disease. Autoimmun Rev 2014;13:24–30. PubMed

Torres J, Cravo M, Colombel JF. Anti-TNF withdrawal in inflammatory bowel disease. GE Port J Gastroenterol 2016;23:153–61. PubMed PMC

Tran V, Shammas RM, Sauk JS, Padua D. Evaluating tofacitinib citrate in the treatment of moderate-to-severe active ulcerative colitis: design, development and positioning of therapy. Clin Exp Gastroenterol 2019;12:179–91. PubMed PMC

Gorfu G, Rivera-Nieves J, Ley K. Role of beta7 integrins in intestinal lymphocyte homing and retention. Curr Mol Med 2009;9:836–50. PubMed PMC

Newham P, Craig SE, Seddon GN, et al. . Alpha4 integrin binding interfaces on VCAM-1 and MAdCAM-1. Integrin binding footprints identify accessory binding sites that play a role in integrin specificity. J Biol Chem 1997;272:19429–40. PubMed

Allavena R, Noy S, Andrews M, Pullen N. CNS elevation of vascular and not mucosal addressin cell adhesion molecules in patients with multiple sclerosis. Am J Pathol 2010;176:556–62. PubMed PMC

Briskin M, Winsor-Hines D, Shyjan A, et al. . Human mucosal addressin cell adhesion molecule-1 is preferentially expressed in intestinal tract and associated lymphoid tissue. Am J Pathol 1997;151:97–110. PubMed PMC

Nakache M, Berg EL, Streeter PR, Butcher EC. The mucosal vascular addressin is a tissue-specific endothelial cell adhesion molecule for circulating lymphocytes. Nature 1989;337:179–81. PubMed

Streeter PR, Berg EL, Rouse BT, Bargatze RF, Butcher EC. A tissue-specific endothelial cell molecule involved in lymphocyte homing. Nature 1988;331:41–6. PubMed

Takeda Pharma A/S. Summary of product characteristics, Entyvio. European Medicines Agency, 2014. https://www.ema.europa.eu/en/documents/product-information/entyvio-epar-product-information_en.pdf. Accessed July, 2019.

Pullen N, Molloy E, Carter D, et al. . Pharmacological characterization of PF-00547659, an anti-human MAdCAM monoclonal antibody. Br J Pharmacol 2009;157:281–93. PubMed PMC

D’Haens G, Vermeire S, Vogelsang H, et al. . Effect of PF-00547659 on central nervous system immune surveillance and circulating beta7+ T cells in Crohn’s disease: report of the TOSCA study. J Crohns Colitis 2018;12:188–96. PubMed PMC

Sandborn WJ, Lee SD, Tarabar D, et al. . Phase II evaluation of anti-MAdCAM antibody PF-00547659 in the treatment of Crohn’s disease: report of the OPERA study. Gut 2018;67:1824–35. PubMed PMC

Vermeire S, Ghosh S, Panes J, et al. . The mucosal addressin cell adhesion molecule antibody PF-00547,659 in ulcerative colitis: a randomised study. Gut 2011;60:1068–75. PubMed

Vermeire S, Sandborn WJ, Danese S, et al. . Anti-MAdCAM antibody [PF-00547659] for ulcerative colitis [TURANDOT]: a phase 2, randomised, double-blind, placebo-controlled trial. Lancet 2017;390:135–44. PubMed

Wang Q, Goetsch M. An electrochemiluminescence [ECL] immunoassay for the detection of anti-drug antibodies against the anti-mucosal addressin cell adhesion molecule [MAdCAM] monoclonal antibody ontamalimab [SHP647]. In: 14th Congress of the European Crohn’s and Colitis Organisation; 2019; Copenhagen, Denmark.

Wang Y, Marier J-F, Lavigne J, Kassir N, Martin P. Population pharmacokinetics and pharmacodynamics of ontamalimab (SHP647), a fully human monoclonal antibody against mucosal addressin cell adhesion molecule-1 (MAdCAM-1), in patients with ulcerative colitis or Crohn’s disease. J Clin Pharmacol 2020;60:903–914. PubMed PMC

Colombel JF, Sands BE, Rutgeerts P, et al. . The safety of vedolizumab for ulcerative colitis and Crohn’s disease. Gut 2017;66:839–51. PubMed PMC

Langer-Gould A, Atlas SW, Green AJ, Bollen AW, Pelletier D. Progressive multifocal leukoencephalopathy in a patient treated with natalizumab. N Engl J Med 2005;353:375–81. PubMed

Van Assche G, Van Ranst M, Sciot R, et al. . Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn’s disease. N Engl J Med 2005;353:362–8. PubMed

Berger JR, Fox RJ. Reassessing the risk of natalizumab-associated PML. J Neurovirol 2016;22:533–5. PubMed

Axelrad JE, Lichtiger S, Yajnik V.. Inflammatory bowel disease and cancer: the role of inflammation, immunosuppression, and cancer treatment. World J Gastroenterol 2016;22:4794–801. PubMed PMC

Giannotta M, Tapete G, Emmi G, Silvestri E, Milla M. Thrombosis in inflammatory bowel diseases: what’s the link? Thromb J 2015;13:14. PubMed PMC

Stuijver DJF, Majoor CJ, van Zaane B, et al. . Use of oral glucocorticoids and the risk of pulmonary embolism: a population-based case-control study. Chest 2013;143:1337–42. PubMed

Peyrin-Biroulet L, Khosrotehrani K, Carrat F, et al. ; Cesame Study Group. Increased risk for nonmelanoma skin cancers in patients who receive thiopurines for inflammatory bowel disease. Gastroenterology 2011;141:1621–8.e1–5. PubMed

Sandborn WJ, Panés J, Zhang H, Yu D, Niezychowski W, Su C. Correlation between concentrations of fecal calprotectin and outcomes of patients with ulcerative colitis in a phase 2 trial. Gastroenterology 2016;150:96–102. PubMed

De Vos M, Dewit O, D’Haens G, et al. ; behalf of BIRD. Fast and sharp decrease in calprotectin predicts remission by infliximab in anti-TNF naïve patients with ulcerative colitis. J Crohns Colitis 2012;6:557–62. PubMed

Henriksen M, Jahnsen J, Lygren I, et al. ; IBSEN Study Group. C-reactive protein: a predictive factor and marker of inflammation in inflammatory bowel disease. Results from a prospective population-based study. Gut 2008;57:1518–23. PubMed